Investor Relations


Zogenix, Inc. (Nasdaq: ZGNX) is a pharmaceutical company committed to developing and commercializing CNS therapies that address specific clinical needs for people living with orphan and other CNS disorders who need innovative treatment alternatives to improve their daily functioning.
NASDAQ | ZGNX (Common Stock)
$8.49 - 0.41
Stock chart for: ZGNX.O.  Currently trading at $8.49 with a 52 week high of $21.65 and a 52 week low of $8.44.
Data as of 02/05/16 4:00 p.m. ET
Data provided by Nasdaq. Minimum 15 minutes delayed.

Latest Presentations

Zogenix January 2016 Investor Presentation
Download Documentation

Recent News More

Zogenix to Participate in LEERINK Partners 5th Annual Global Healthcare Conference

Read More

Zogenix Receives Fast Track Designation From FDA for Development of ZX008 in Dravet Syndrome

Read More

Investor Events More

Wednesday, November 18, 2015 11:00 a.m. ET
Zogenix, Inc. at Stifel 2015 Healthcare Conference